Seifert E
I. Med. Klinik, Städt. Krankenhaus Kemperhof Koblenz.
Leber Magen Darm. 1994 Mar;24(2):66-8, 71.
Lansoprazole, a new proton pump inhibitor, selectively inhibits the H+/K(+)-ATPase. Its inhibitory effect on basal and gastrin stimulated gastric acid secretion is equal to omeprazole and stronger than that of H2-receptor antagonists. Healing rates concerning gastric and duodenal ulcers and refluxesophagitis are significantly higher compared to H2-receptor antagonists and at least comparable to omeprazole. Regarding pilot studies in H. pylori eradication therapy, lansoprazole in combination with various antibiotics is expected to show good eradication rates. Considering its excellent safety and interaction profile lansoprazole is effective and safe in treating acid related disorders.
兰索拉唑是一种新型质子泵抑制剂，可选择性抑制H⁺/K⁺-ATP酶。它对基础胃酸分泌和胃泌素刺激的胃酸分泌的抑制作用与奥美拉唑相当，且强于H₂受体拮抗剂。与H₂受体拮抗剂相比，兰索拉唑对胃溃疡、十二指肠溃疡和反流性食管炎的愈合率显著更高，且至少与奥美拉唑相当。在幽门螺杆菌根除治疗的初步研究中，预计兰索拉唑与各种抗生素联合使用将显示出良好的根除率。鉴于其出色的安全性和相互作用情况，兰索拉唑在治疗酸相关疾病方面有效且安全。
